Side effects of moving from Wegovy 0.25mg to 0.5mg

What the 0.25mg and 0.5mg doses are actually doing to your body

Semaglutide activates GLP-1 receptors in the gut and brain, slowing how quickly the stomach empties and signalling fullness earlier. At the starting dose the effect is deliberately modest, the prescriber is giving your system time to adjust before the dose rises. The 0.25mg starter phase typically lasts four weeks; the move to 0.5mg is the first real dose step.

Slowed gastric emptying is the source of most early symptoms. Food spends longer in the stomach, which can feel uncomfortable, cause nausea after eating, or produce reflux and burping. At the same time, gut motility changes lead some people to experience constipation, others loose stools, sometimes both in alternation. Headache and mild fatigue are also reported, particularly in the first week at a new dose.

The NHS Medicines page for semaglutide lists the full side-effect profile with frequency data. Most early symptoms are described as mild to moderate and transient, settling as the body acclimatises over days to two weeks. If yours have not eased by the time the next injection is due, that is worth raising with your prescriber rather than assuming it will pass.

A quick check worth doing at any point: scan your symptom against its timing. Nausea that peaks in the 24–48 hours after the injection then fades is typical early adjustment. Symptoms that arrive days later, worsen over time, or have no clear link to injection day are worth flagging.

Side effects that are more common than people expect at low doses

People sometimes assume that a low dose means a low side-effect burden. That is not always true, the gut's sensitivity to GLP-1 stimulation does not scale neatly with the milligram figure. Some people tolerate 2.4mg more comfortably than their first pen at 0.25mg; others have a more settled journey from the start.

The most commonly reported effects at these early doses, drawn from the 0.5mg dose experience specifically:

• Nausea, particularly after eating a large or fatty meal
• Constipation, which responds to hydration and dietary fibre
• Diarrhoea or loose stools
• Indigestion and upper abdominal discomfort
• Burping and reflux
• Tiredness and mild headache

Practical adjustments that prescribers commonly discuss include eating smaller portions, avoiding very rich foods around injection day, and keeping well hydrated. These are not treatment instructions, your own prescriber and the patient information leaflet are the right sources for personalised guidance on managing early symptoms.

On the full Wegovy dose schedule there are four more steps above 0.5mg. The early dose stages are specifically designed to reduce the chance that tolerability problems accumulate later. Rushing through them is not advisable.

When side effects become a reason to get medical help

The distinction between expected adjustment and a signal requiring action matters. The following warrant prompt medical attention, this is not an exhaustive list, and your patient information leaflet and prescriber guidance take precedence.

Seek urgent help for: severe, persistent abdominal pain, especially pain that spreads toward the back, with or without vomiting. This pattern can indicate acute pancreatitis, an infrequent but serious risk. In January 2026, the MHRA issued a Drug Safety Update specifically drawing attention to this for GLP-1 medicines; the update asks patients and prescribers to be vigilant even at lower doses.

Also seek help for signs of gallbladder problems (severe pain in the upper right abdomen), symptoms of significant dehydration from prolonged vomiting or diarrhoea (dizziness, very dark urine, not passing urine), and any signs of a serious allergic reaction including facial swelling or difficulty breathing.

Less urgently but still worth a call to your prescriber: nausea that is stopping you eating or drinking adequately, symptoms that are not settling after two weeks, or any side effect you are unsure about. Our prescribers at nume are available seven days a week for aftercare, that access is part of the service, not an add-on.

You can also report suspected side effects directly to the MHRA via the Yellow Card scheme. Reporting, even for symptoms you are uncertain about, helps build the evidence base for medicines at every stage of use.

What comes next on the Wegovy schedule, and how to approach it

Moving from 0.5mg to the next step, 1mg, follows the same four-week pattern. For most people the side-effect experience at 1mg tracks what they encountered at lower doses, sometimes with a brief re-emergence of early nausea as the dose rises. The pattern tends to become predictable, most people know by their second or third dose step how their body responds in the days after the injection.

If the 0.5mg step has been difficult, the right conversation is with your prescriber before progressing. Staying at a dose for longer than the standard four weeks is sometimes appropriate; that is a clinical judgement. General guidance on the full titration arc is set out on the Wegovy treatment overview.

The full dose schedule runs to 2.4mg, and for eligible patients approved for the higher dose, on to 7.2mg. How the side-effect profile shifts at those levels is a separate question, 2.4mg side effects are covered in detail on their own page. The early steps exist precisely to make the higher doses more manageable.

If you have questions about suitability for Wegovy or want to discuss how side effects might interact with your specific health picture, speak to our prescribers as part of your free consultation. It is the right place for those questions, and it costs nothing to ask.